Business Context and Reporting Period
This Form 8-K, filed on July 27, 2015, reports on events occurring on July 23, 2015. The registrant, Anthem, Inc. (now Elevance Health), entered into a definitive Agreement and Plan of Merger with Cigna Corporation. The transaction involves a two-step merger structure intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code, with Anthem surviving as the combined entity.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed merger and financing arrangements rather than historical operating results.
- Merger Consideration: Cigna shareholders will receive $103.40 in cash and 0.5152 shares of Anthem common stock for each share of Cigna common stock held.
- Financing Facility: Anthem secured a commitment letter for a 364-day senior unsecured bridge term loan credit facility of up to $26.5 billion to finance the transaction if permanent financing is not secured prior to closing.
- Termination Fees: A termination fee of $1.85 billion is payable under specific circumstances, including failure to obtain shareholder approval or entering into a superior proposal. An expense fee of $600 million is payable if shareholder approval is not obtained.
- Reverse Termination Fee: Cigna is entitled to a reverse termination fee of $1.85 billion if the merger fails due to regulatory restraints or failure to close by the specified deadline (January 31, 2017, extendable to April 30, 2017) while other conditions are met.
Note: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Governance
The primary material change is the entry into the Merger Agreement. Upon consummation:
- Leadership: Joseph Swedish will serve as Chairman of the Board and CEO of the surviving corporation. David Cordani will serve as President and Chief Operating Officer.
- Board Composition: The board of directors will expand to 14 members, consisting of nine current Anthem directors and five current Cigna directors.
- Corporate Name: The surviving corporation will retain the name Anthem, Inc.
Guidance, Risks, and Contingencies
The filing includes a Safe Harbor Statement regarding forward-looking information, noting that actual results may differ due to various risks.
- Conditions to Closing: The merger is subject to shareholder approval from both companies, receipt of necessary governmental and regulatory approvals without "Burdensome Terms," listing of shares on the NYSE, and the absence of legal restraints.
- Key Risks: Risks include the failure to achieve expected synergies, integration disruptions, regulatory challenges (including the Affordable Care Act), changes in healthcare costs, and the potential for the transaction not to close.
- Outlook: Management intends to use reasonable best efforts to consummate the merger, subject to fiduciary duties and the possibility of a superior proposal.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement in the joint proxy statement/prospectus (Form S-4) once filed.
- Monitor the status of regulatory approvals and any potential "Burdensome Terms" imposed by government agencies.
- Confirm the outcome of shareholder votes for both Anthem and Cigna.
- Review the definitive financing arrangements to determine if the $26.5 billion bridge facility is utilized or replaced by permanent debt/equity.
- Assess the impact of the merger on Anthem's debt-to-capital ratio and credit ratings post-closing.